Steven Kelly has been the President and CEO of CARISMA Therapeutics since February 2018. Before leading CARISMA, Mr. Kelly was the founding CEO of Pinteon Therapeutics, an early-stage Oncology, and CNS development company.
Prior to this, he held a number of leadership positions in the biotechnology industry including: CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen. Mr. Kelly holds a BS from the University of Oregon and an MBA from Cornell University.